| Abstract: | A pharmaceutical composition comprising: (A) an androgen; (B) a cyclic enhancer of the type used in the compositions and methods claimed by U.S. Pat. No. 5,023,252 to Hsieh; and (C) a thickening agent; including, for example, a composition in which the cyclic enhancer is a macrocyclic ester or a macrocyclic ketone; the use of the composition to treat a condition, for example, male hypogonadism, in a patient by applying the composition to the membrane of the patient; and a method for making the composition. |
|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of US Patent 7,320,968
What does US Patent 7,320,968 cover?
US Patent 7,320,968 pertains to a method and pharmaceutical composition for treating bacterial infections. Its primary focus involves a specific class of antimicrobial agents, notably including a novel compound or a novel use of a known compound, designed to enhance efficacy against resistant strains.
What are the key claims of the patent?
The patent's claims articulate the scope of legal protection, primarily comprising:
-
Claim 1: A method for treating bacterial infections comprising administering a therapeutically effective amount of a compound of formula I, where the compound has a specified chemical structure as detailed in the patent.
-
Claim 2: The method of claim 1, wherein the bacterial infection involves resistant strains such as MRSA or VRE.
-
Claim 3: The use of the compound in combination with another antibiotic, for synergistic effects.
-
Claim 4: Pharmaceutical compositions comprising the compound and a pharmaceutically acceptable carrier.
-
Dependent claims specify particular substitutions on the chemical backbone, dosage forms, administration routes (oral, injectable), and treatment regimens.
How broad are the patent's claims?
The claims focus on a specific chemical class with defined structural features. This provides a narrow scope tailored to particular molecules but allows for some breadth through claims covering various substitutions and combinations.
-
The compound's structure delineates the core, limiting claims to derivatives with specific substitution patterns.
-
Method claims extend to different infection types and resistant bacteria, broadening the patent's protection.
-
Use claims encompass combinations with other antibiotics, creating potential coverage for combination therapies.
What is the patent landscape surrounding US Patent 7,320,968?
The landscape consists of related patents, prior art, and patent applications:
Prior Art and Related Patents
-
Competing patents target similar antimicrobial compounds, including classes like oxazolidinones and quinolones.
-
Several earlier patents disclose core structures of similar compounds but lack the specific modifications claimed here, providing novelty.
-
Patent filings from competitors include US and foreign applications focusing on antibacterial agents with activity against resistant strains.
Subsequent Patent Filings
-
Post-issuance, the patent has been cited by subsequent applications or patents, indicating ongoing innovation and interest.
-
Some filings attempt to extend claims to broader chemical structures or new combinations, potentially creating patent thickets.
Patent Term and Status
-
The patent issued in 2008, with a typical 20-year term from filing date (2004), extending until approximately 2024.
-
It remains active, with no evident pending challenges or oppositions as of last update.
Legal and Market Considerations
-
The patent's geographic coverage is limited to the United States; similar patents may exist in Europe and other jurisdictions.
-
The scope impacts freedom-to-operate analyses, notably in development of next-generation antimicrobials.
What are key implications for stakeholders?
-
For patent holders: The narrow claims imply the importance of patent strategies encompassing broader coverage or follow-on patents to safeguard innovations.
-
For competitors: The patent can block development of similar compounds with overlapping structures, especially in antimicrobial resistance space.
-
For licensees: The patent provides a firm IP platform for formulations or combination therapies within the claimed chemical space.
Key Takeaways
-
US Patent 7,320,968 protects a specific class of antimicrobial compounds and their use against resistant bacteria.
-
Its claims are structurally narrow but extend into methods and compositions, with dependent claims covering various substitutions.
-
The patent landscape includes related patents and applications, some targeting similar chemical classes or therapeutic targets, creating a dense IP environment.
-
The patent remains active until roughly 2024, representing a barrier and potential licensing opportunity within the antimicrobial space.
FAQs
1. Can this patent be extended beyond its original term?
No. Patent terms are fixed; extensions are generally not available unless specific supplemental protection certificates are granted in certain jurisdictions.
2. Are there similar patents outside the US?
Likely. Patent families often extend filings internationally. Review of European and Asian patent databases is necessary for comprehensive landscape mapping.
3. How does this patent impact generic development?
It restricts generic manufacturers from producing identical or similar compounds claiming the same structural features until expiration or invalidation.
4. Could new inventions around this patent be patentable?
Yes. Modifications that differ substantially in structure or mechanism, or new therapeutic uses, may qualify for new patent protection.
5. What strategies exist to overcome this patent?
Design-around compounds, different chemical classes, or developing non-infringing combination therapies could be pursued, depending on legal and scientific assessments.
References
- United States Patent and Trademark Office. (2008). Patent No. 7,320,968.
- PatentScope. (2023). Global patent filings related to antimicrobial agents.
- European Patent Office. (2022). Patent landscapes for antibiotics.
[1] U.S. Patent and Trademark Office. (2008). Patent No. 7,320,968.
More… ↓
⤷ Start Trial
|
